Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment.
Björklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S, Ahlberg AJ, Kauric G, Mäntymaa P, Osnes L, Penttilä TL, Marquart H, Savolainen ER, Siitonen S, Torikka K, Mazur J, Porwit A. Björklund E, et al. Among authors: siitonen s. J Pediatr Hematol Oncol. 2009 Jun;31(6):406-15. doi: 10.1097/MPH.0b013e3181a1c0e8. J Pediatr Hematol Oncol. 2009. PMID: 19648789
Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.
Tierens A, Bjørklund E, Siitonen S, Marquart HV, Wulff-Juergensen G, Pelliniemi TT, Forestier E, Hasle H, Jahnukainen K, Lausen B, Jonsson OG, Palle J, Zeller B, Fogelstrand L, Abrahamsson J. Tierens A, et al. Among authors: siitonen s. Br J Haematol. 2016 Aug;174(4):600-9. doi: 10.1111/bjh.14093. Epub 2016 Apr 13. Br J Haematol. 2016. PMID: 27072379 Free article.
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: siitonen sm. Leukemia. 2019 Jun;33(6):1324-1336. doi: 10.1038/s41375-018-0307-6. Epub 2018 Dec 14. Leukemia. 2019. PMID: 30552401
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
Modvig S, Hallböök H, Madsen HO, Siitonen S, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Matuzeviciene R, Stoskus M, Marincevic M, Lilleorg A, Ehinger M, Norén-Nystrøm U, Toft N, Taskinen M, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Porwit A, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: siitonen s. Leukemia. 2021 Jul;35(7):1894-1906. doi: 10.1038/s41375-020-01100-5. Epub 2020 Dec 14. Leukemia. 2021. PMID: 33318611 Free PMC article.
T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.
Quist-Paulsen P, Toft N, Heyman M, Abrahamsson J, Griškevičius L, Hallböök H, Jónsson ÓG, Palk K, Vaitkeviciene G, Vettenranta K, Åsberg A, Frandsen TL, Opdahl S, Marquart HV, Siitonen S, Osnes LT, Hultdin M, Overgaard UM, Wartiovaara-Kautto U, Schmiegelow K. Quist-Paulsen P, et al. Among authors: siitonen s. Leukemia. 2020 Feb;34(2):347-357. doi: 10.1038/s41375-019-0598-2. Epub 2019 Oct 14. Leukemia. 2020. PMID: 31611626
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: siitonen sm. Leukemia. 2020 Jun;34(6):1719-1720. doi: 10.1038/s41375-019-0672-9. Leukemia. 2020. PMID: 31822778
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.
Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Huotari V, Mäntymaa P, Siitonen S, Uotila L, Penttilä TL, Juvonen V, Selander T, Remes K. Silvennoinen R, et al. Among authors: siitonen s. Blood Cancer J. 2014 Oct 10;4(10):e250. doi: 10.1038/bcj.2014.69. Blood Cancer J. 2014. PMID: 25303369 Free PMC article. Clinical Trial.
Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study.
Lacombe F, Bernal E, Bloxham D, Couzens S, Porta MG, Johansson U, Kern W, Macey M, Matthes T, Morilla R, Paiva A, Palacio C, Preijers F, Ratei R, Siitonen S, Allou K, Porwit A, Béné MC. Lacombe F, et al. Among authors: siitonen s. Leukemia. 2016 Aug;30(8):1769-72. doi: 10.1038/leu.2016.44. Epub 2016 Feb 29. Leukemia. 2016. PMID: 26922887 No abstract available.
90 results